Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework

Optimal pharmacokinetic (PK) properties of therapeutic monoclonal antibodies (mAbs) are essential to achieve the desired pharmacological benefits in patients. To accomplish this, we followed an approach comprising structure-based mAb charge engineering in conjunction with the use of relevant preclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ollier, Romain, Fuchs, Aline, Gauye, Florence, Piorkowska, Katarzyna, Menant, Sébastien, Ratnam, Monisha, Montanari, Paolo, Guilhot, Florence, Phillipe, Didier, Audrain, Mickael, Egesipe, Anne-Laure, Névoltris, Damien, Seredenina, Tamara, Pfeifer, Andrea, Kosco-Vilbois, Marie, Afroz, Tariq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324452/
https://www.ncbi.nlm.nih.gov/pubmed/37408314
http://dx.doi.org/10.1080/19420862.2023.2232087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324452/
https://www.ncbi.nlm.nih.gov/pubmed/37408314
http://dx.doi.org/10.1080/19420862.2023.2232087

Ejemplares similares